Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

McGill University

$120,000.00

Strategies to Reduce the Recurrence Rate of Clostridioides difficile Infections

EF 2025-26

Résumé
Clostridioides difficile (C. difficile) is a bacterial infection of the colon that can cause life-threatening diarrhea. It is the most common hospital-acquired infection, with over 16,000 cases reported yearly in Canada. The attributable cost of C. difficile in Canada is over 250 million dollars annually. Antibiotic use, which depletes the healthy gut flora is the strongest risk factor for C. difficile infection. While C. difficile is treatable with oral C. difficile-active antibiotics, 20-30% of patients will have a recurrence of the infection within 60 days of treatment. The most common cause of recurrence is antibiotic use for another infection (referred to as systemic antibiotics), which occurs in 30-40% of patients recovering from C. difficile. Oral vancomycin is the first-line treatment for C. difficile in Canada and is very safe, inexpensive, and accessible. Some studies have suggested that giving low-dose oral vancomycin during systemic antibiotics in patients with recent C. difficile infection may reduce the risk of recurrent C. difficile. However, the data is heterogeneous and of poor quality. Therefore, we aim to conduct a review of the current evidence on vancomycin prophylaxis, an international survey of C. difficile prophylaxis, and, ultimately, to conduct a randomized controlled trial comparing vancomycin to placebo for the prevention of recurrent C. difficile in patients re-exposed to systemic antibiotics. These studies will inform the use of vancomycin for the prevention of recurrent C. difficile and may reduce the recurrence rate of C. difficile.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
560192
Name
Prosty Connor
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
DT2 (Health services and population health research) CGRS Doctoral
Projecttitle
Strategies to Reduce the Recurrence Rate of Clostridioides difficile Infections
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Clinical Trial; Clostridioides Difficile; Diarrhea; Fidaxomicin; Infectious Diseases; Prophylaxis; Recurrence; Survey; Systematic Review; Vancomycin
Abstract
Clostridioides difficile (C. difficile) is a bacterial infection of the colon that can cause life-threatening diarrhea. It is the most common hospital-acquired infection, with over 16,000 cases reported yearly in Canada. The attributable cost of C. difficile in Canada is over 250 million dollars annually. Antibiotic use, which depletes the healthy gut flora is the strongest risk factor for C. difficile infection. While C. difficile is treatable with oral C. difficile-active antibiotics, 20-30% of patients will have a recurrence of the infection within 60 days of treatment. The most common cause of recurrence is antibiotic use for another infection (referred to as systemic antibiotics), which occurs in 30-40% of patients recovering from C. difficile. Oral vancomycin is the first-line treatment for C. difficile in Canada and is very safe, inexpensive, and accessible. Some studies have suggested that giving low-dose oral vancomycin during systemic antibiotics in patients with recent C. difficile infection may reduce the risk of recurrent C. difficile. However, the data is heterogeneous and of poor quality. Therefore, we aim to conduct a review of the current evidence on vancomycin prophylaxis, an international survey of C. difficile prophylaxis, and, ultimately, to conduct a randomized controlled trial comparing vancomycin to placebo for the prevention of recurrent C. difficile in patients re-exposed to systemic antibiotics. These studies will inform the use of vancomycin for the prevention of recurrent C. difficile and may reduce the recurrence rate of C. difficile.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Prosty, Connor
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~